Acumen Pharmaceuticals Eyes Late 2026 Data for Alzheimer’s Drug as Cash Runs to 202712 May 2026 16:30
- Acumen expects topline results from ALTITUDE-AD Phase 2 study of sabirnetug for early Alzheimer’s disease in late 2026.
- Cash position of $128.4 million as of March 31, 2026, expected to support operations into early 2027.
- Plans to license two compounds from JCR Pharmaceuticals collaboration in Q2 2026.
- R&D expenses decreased to $16.5 million in Q1 2026 from $25.3 million in Q1 2025.
- Targeting mid-2027 IND filing for lead clinical candidate in EBD program.
https://briefglance.com/companies/acumen-pharmaceuticals-inc/pulses/16479